MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.currproblcancer.2024.101075

Медицинская библиотека · Current problems in cancer · 2024

MET alterations in advanced non-small cell lung cancer.

Chagas Gabriel Cavalcante Lima, Rangel Amanda Ribeiro, El Osta Badi

СтатьяОбзорПеревод в очереди

Аннотация

Precision medicine has helped identify several tumor molecular aberrations to be treated with targeted therapies. These therapies showed substantial improvement in efficacy without excessive toxicity in patients with specific oncogenic drivers with advanced cancers. In metastatic lung cancers, the implementation of broad platforms for molecular tumor sequencing has helped oncology providers identify oncogenic drivers linked with better outcomes when treated upfront with targeted therapies. Mesenchymal-epithelial transition factor (MET) alterations are present in up to 60% of non-small cell lung cancer and are associated with a poor prognosis. Capmatinib and tepotinib are currently the only two approved targeted therapies by the U.S. Food and Drug Administration (FDA) for patients with MET exon 14 skipping mutation. Several agents are being developed to tackle an unmet need in patients with MET alterations. Some of these agents are being used in combination with EGFR targeted therapy to mitigate resistance to EGFR inhibitor. These agents are poised to provide new hope for these patients.

Для цитирования: Chagas Gabriel Cavalcante Lima, Rangel Amanda Ribeiro, El Osta Badi. MET alterations in advanced non-small cell lung cancer.. Current problems in cancer. 2024. DOI: 10.1016/j.currproblcancer.2024.101075.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.